AU4597496A – Liposome-mediated transfection of central nervous system cells
– Google Patents
AU4597496A – Liposome-mediated transfection of central nervous system cells
– Google Patents
Liposome-mediated transfection of central nervous system cells
Info
Publication number
AU4597496A
AU4597496A
AU45974/96A
AU4597496A
AU4597496A
AU 4597496 A
AU4597496 A
AU 4597496A
AU 45974/96 A
AU45974/96 A
AU 45974/96A
AU 4597496 A
AU4597496 A
AU 4597496A
AU 4597496 A
AU4597496 A
AU 4597496A
Authority
AU
Australia
Prior art keywords
liposome
nervous system
central nervous
mediated transfection
system cells
Prior art date
1994-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45974/96A
Inventor
Fabrizia Faustinella
Ronald L. Hayes
Keyi Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1994-12-12
Filing date
1995-12-11
Publication date
1996-07-03
1995-12-11
Application filed by Individual
filed
Critical
Individual
1996-07-03
Publication of AU4597496A
publication
Critical
patent/AU4597496A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K9/00—Medicinal preparations characterised by special physical form
A61K9/10—Dispersions; Emulsions
A61K9/127—Liposomes
A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
C07K14/475—Growth factors; Growth regulators
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
C07K14/475—Growth factors; Growth regulators
C07K14/48—Nerve growth factor [NGF]
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
AU45974/96A
1994-12-12
1995-12-11
Liposome-mediated transfection of central nervous system cells
Abandoned
AU4597496A
(en)
Applications Claiming Priority (3)
Application Number
Priority Date
Filing Date
Title
US08/353,901
US6096716A
(en)
1994-12-12
1994-12-12
Liposome-mediated transfection of central nervous system cells
US353901
1994-12-12
PCT/US1995/016081
WO1996018741A2
(en)
1994-12-12
1995-12-11
Liposome-mediated transfection of central nervous system cells
Publications (1)
Publication Number
Publication Date
AU4597496A
true
AU4597496A
(en)
1996-07-03
Family
ID=23391066
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU45974/96A
Abandoned
AU4597496A
(en)
1994-12-12
1995-12-11
Liposome-mediated transfection of central nervous system cells
Country Status (4)
Country
Link
US
(1)
US6096716A
(en)
EP
(1)
EP0804605A2
(en)
AU
(1)
AU4597496A
(en)
WO
(1)
WO1996018741A2
(en)
Families Citing this family (31)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US6551618B2
(en)
*
1994-03-15
2003-04-22
University Of Birmingham
Compositions and methods for delivery of agents for neuronal regeneration and survival
EP0969876A2
(en)
*
1997-04-17
2000-01-12
Paola Leone
Delivery system for gene therapy to the brain
AU5945301A
(en)
*
2000-05-05
2001-11-20
Res Foundation Of City Univers
Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
WO2004071426A2
(en)
*
2003-02-11
2004-08-26
Kemia Inc.
Compounds for the treatment of viral infection
CA2566549C
(en)
2004-05-12
2014-01-14
The Walter And Eliza Hall Institute Of Medical Research
A method for isolating mammary stem cells
US20060211004A1
(en)
2005-02-15
2006-09-21
Ilsley Diane D
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
WO2006126208A2
(en)
2005-05-26
2006-11-30
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US8686110B2
(en)
2005-06-24
2014-04-01
The Walter And Eliza Hall Institute Of Medical Research
Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
EP2602326B1
(en)
2005-12-13
2018-08-22
The Trustees Of The University Of Pennsylvania
Methods for transfecting nucleic acids into live cells
US10647960B2
(en)
2005-12-13
2020-05-12
The Trustees Of The University Of Pennsylvania
Transcriptome transfer produces cellular phenotype conversion
US9157066B2
(en)
2005-12-13
2015-10-13
The Trustees Of The University Of Pennsylvania
Transcriptome transfer produces cellular phenotype conversion
US9149543B2
(en)
*
2005-12-15
2015-10-06
The Trustees Of The University Of Pennsylvania
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
CN101426536A
(en)
2006-01-20
2009-05-06
妇女儿童健康研究院公司
Method of treatment, prophylaxis and diagnosis of pathologies of the bone
WO2007098541A1
(en)
*
2006-02-28
2007-09-07
Regenertech Pty Limited
Tissue regeneration ii
CA2647246C
(en)
*
2006-03-30
2015-06-23
Research Foundation Of City University Of New York
Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2008052766A2
(en)
*
2006-11-03
2008-05-08
Medigene Ag
Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
JP5659014B2
(en)
2007-08-02
2015-01-28
ジリード バイオロジクス，インク．
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis and metastasis
US9265843B2
(en)
2008-03-27
2016-02-23
The Ohio State University
Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
WO2011088462A2
(en)
2010-01-18
2011-07-21
Albany Medical College
Alpha-fetoprotein ‘ring and tail’ peptides
US9884909B2
(en)
2010-12-01
2018-02-06
Alderbio Holdings Llc
Anti-NGF compositions and use thereof
US11214610B2
(en)
2010-12-01
2022-01-04
H. Lundbeck A/S
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2
(en)
2010-12-01
2015-07-14
Alderbio Holdings Llc
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2
(en)
2010-12-01
2017-01-10
Alderbio Holdings, Llc
Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2
(en)
2010-12-01
2015-06-30
Alderbio Holdings Llc
Methods of preventing or treating pain using anti-NGF antibodies
US8911734B2
(en)
2010-12-01
2014-12-16
Alderbio Holdings Llc
Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
SG11201400916XA
(en)
2011-08-22
2014-06-27
Cangene Corp
Clostridium difficile antibodies
US9783841B2
(en)
*
2012-10-04
2017-10-10
The Board Of Trustees Of The Leland Stanford Junior University
Detection of target nucleic acids in a cellular sample
SG10201806481XA
(en)
2014-02-19
2018-09-27
Emergent Biosolutions Canada Inc
Marburg monoclonal antibodies
EP3155016A1
(en)
2014-06-11
2017-04-19
Gilead Sciences, Inc.
Methods for treating cardiovascular diseases
WO2017040932A1
(en)
2015-09-04
2017-03-09
Primatope Therapeutics Inc.
Humanized anti-cd40 antibodies and uses thereof
US10149887B2
(en)
2015-10-23
2018-12-11
Canbas Co., Ltd.
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
Family Cites Families (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5073543A
(en)
*
1988-07-21
1991-12-17
G. D. Searle & Co.
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
AU3129793A
(en)
*
1991-11-08
1993-06-07
General Hospital Corporation, The
Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1993025673A1
(en)
*
1992-06-04
1993-12-23
The Regents Of The University Of California
In vivo gene therapy with intron-free sequence of interest
1994
1994-12-12
US
US08/353,901
patent/US6096716A/en
not_active
Expired – Fee Related
1995
1995-12-11
EP
EP95944086A
patent/EP0804605A2/en
not_active
Withdrawn
1995-12-11
AU
AU45974/96A
patent/AU4597496A/en
not_active
Abandoned
1995-12-11
WO
PCT/US1995/016081
patent/WO1996018741A2/en
not_active
Application Discontinuation
Also Published As
Publication number
Publication date
US6096716A
(en)
2000-08-01
EP0804605A2
(en)
1997-11-05
WO1996018741A2
(en)
1996-06-20
WO1996018741A3
(en)
1996-08-29
Similar Documents
Publication
Publication Date
Title
AU4597496A
(en)
1996-07-03
Liposome-mediated transfection of central nervous system cells
AU7612196A
(en)
1997-06-05
Functional human hematopoietic cells
AU5393796A
(en)
1996-11-18
Bioreactor
AU1688695A
(en)
1995-08-21
Adenoviral-mediated method of cell transfection
AU5934396A
(en)
1996-12-11
Improved battery design
AU5048596A
(en)
1996-10-17
Improved electrode
AU6497696A
(en)
1997-04-01
Electrode
AU5064196A
(en)
1996-10-24
Photochemical cell
AU4818396A
(en)
1996-09-26
Battery
AU5228296A
(en)
1996-11-28
Holder fitting structure
AU7073096A
(en)
1997-04-09
Inhibited biological degradation of oligodeoxynucleotides
AU6859096A
(en)
1997-04-09
Substituted cyclohexylamines as central nervous system agents
AU4783196A
(en)
1996-09-11
Electrode arrangement and stimulation system
AU678952B2
(en)
1997-06-12
Multi-element battery
AU2682895A
(en)
1996-01-05
EG Cells of Ungulates
AU4224096A
(en)
1996-08-08
Use of phenylcyclohexylcarboxamides
AU6130196A
(en)
1997-01-22
Cell treatment
AU6015196A
(en)
1997-02-05
Voltage regulator
AU3308695A
(en)
1996-04-18
Regulated genes by stimulation of chondrocytes with IL-1beta
AU4677496A
(en)
1996-09-11
Use of helioxanthin as an enhancer of cell differentiation inducing factors
AU3586595A
(en)
1996-03-27
Preparation of immortalized cells
AU6225696A
(en)
1997-01-22
An extended cell system
AU2104497A
(en)
1997-10-10
Cell stimulation
AU7505696A
(en)
1997-05-29
Autoantigen
AU2707897A
(en)
1997-12-05
Direct electrochemistry of enzymes
None